An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation in adult patients.
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Inolimomab (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors EUSA Pharma
- 15 Aug 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 28 Jun 2012 Planned end date changed from 15 May 2009 to 15 Jan 2012 as reported by European Clinical Trials Database record.
- 25 Aug 2011 New trial record